|1.||Parsons, A A: 4 articles (04/2001 - 03/2000)|
|2.||Upton, N: 4 articles (04/2001 - 03/2000)|
|3.||Olesen, J: 3 articles (11/2009 - 10/2004)|
|4.||Martelletti, Paolo: 2 articles (09/2012 - 10/2009)|
|5.||Olesen, Jes: 2 articles (06/2011 - 08/2009)|
|6.||Silberstein, S D: 2 articles (11/2009 - 11/2009)|
|7.||Thompson, M: 2 articles (04/2001 - 07/2000)|
|8.||Smith, M I: 2 articles (07/2000 - 03/2000)|
|9.||Read, S J: 2 articles (07/2000 - 03/2000)|
|10.||Hunter, A J: 2 articles (07/2000 - 03/2000)|
|1.||Migraine Disorders (Migraine)
01/01/2014 - "Although tonabersat failed to demonstrate a significantly greater reduction of migraine headache days than placebo, it was well tolerated. "
01/01/2014 - "Randomized clinical trials assessing the efficacy and tolerability of tonabersat compared with placebo as prophylaxis for migraine were systematically reviewed in this study. "
11/01/2009 - "In preclinical and clinical trials, tonabersat was well tolerated, with no cardiovascular effects; the pharmacokinetic profile suggested its usefulness in the prophylaxis of migraine."
11/01/2009 - "The ability of single oral doses of 15, 25, 40 and 80 mg of tonabersat to relieve the symptoms of moderate to severe migraine was evaluated in 859 migraineurs enrolled in two dose-ranging, double-blind, randomized, placebo-controlled, parallel-group trials, one international and the other North American. "
11/01/2009 - "Tonabersat, a gap-junction modulator: efficacy and safety in two randomized, placebo-controlled, dose-ranging studies of acute migraine."
08/01/2009 - "In this randomised, double-blind, placebo-controlled crossover trial, 40 mg tonabersat once daily was compared with matched placebo in patients who had at least one aura attack per month during the past 3 months. "
11/01/2009 - "The ability of tonabersat to relieve the symptoms of migraine attacks with or without aura was evaluated in a randomized, double-blind, placebo-controlled, multicentre, parallel-group study. "
01/01/2014 - "In contrast, in another clinical trial, tonabersat showed a preventive effect on attacks of migraine with aura but had no efficacy on non-aura attacks. "
08/01/2009 - "Tonabersat showed a preventive effect on attacks of migraine aura but no efficacy on non-aura attacks, in keeping with its known inhibitory effect on CSD. "
08/01/2009 - "Median (IQR) attacks of aura were reduced from 3.2 (1.0-5.0) per 12 weeks on placebo to 1.0 (0-3.0) on tonabersat (p=0.01), whereas the other primary outcome measure, median migraine headache days with or without aura, was not significantly different between placebo and tonabersat groups (3.0 days in each group; p=0.09). "
01/01/2014 - "Computerized database search of The Cochrane Pain, Palliative & Supportive Care Trials Register, The Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library), Pubmed, and EMBASE for randomized, double-blind, placebo-controlled trials on tonabersat for migraine until January, 2013. "
11/01/2009 - "In the international study, significantly more patients given tonabersat than given placebo experienced relief of headache pain at 2 h (15 mg, 36.8%; 40 mg, 40.7%), the principal efficacy variable, and at 4 h (40 mg, 63.0%) and complete abolition of headache at 4 h (40 mg, 34.3%). "
|2.||Type A Botulinum Toxins (Botulinum A Toxin)
|3.||Glutamic Acid (Glutamate)
|4.||Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)
|5.||Serotonin Receptor Agonists (Serotonin Receptor Agonist)
|7.||Valproic Acid (Valproate, Semisodium)
|8.||Nitric Oxide (Nitrogen Monoxide)
|10.||Anticonvulsants (Antiepileptic Drugs)